Nautilus Biotechnology, Inc.

NasdaqGS NAUT

Nautilus Biotechnology, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024

Nautilus Biotechnology, Inc. Return on Equity (ROE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Nautilus Biotechnology, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -20.19%, a -15.48% change year over year.
Nautilus Biotechnology, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -17.49%, a 21.34% change year over year.
Nautilus Biotechnology, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -22.23%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGS: NAUT

Nautilus Biotechnology, Inc.

CEO	Mr. Sujal M. Patel
IPO Date	Aug. 7, 2020
Location	United States
Headquarters	2701 Eastlake Avenue East
Employees	161
Sector	Technology
Industries Big Data 3D Printing Biotechnology Credit Cards & Payments Database Fintech Pharmaceuticals

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Key trends

Past 5 years